{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:21:01Z","timestamp":1768530061815,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12094-021-02567-z","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T17:03:34Z","timestamp":1618851814000},"page":"1666-1677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA\/TTCC-2010-06 study"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-2573","authenticated-orcid":false,"given":"J.","family":"Mart\u00ednez-Trufero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lozano Borbalas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Pajares Bernad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Taberna Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ortega Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Cirauqui Cirauqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rubi\u00f3-Casadevall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Plana Serrahima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Ponce Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Planas Toledano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Marruecos Querol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Iglesias Docampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lambea Sorrosal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Adansa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mes\u00eda Nin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Grupo Espa\u00f1ol de Tratamiento de Tumores de Cabeza y Cuello (TTCC)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"2567_CR1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ijrobp.2017.02.022","volume":"98","author":"R Maggiore","year":"2017","unstructured":"Maggiore R, Zumsteg ZS, BrintzenhofeSzoc K, et al. The older adult with locoregionally advanced head and neck squamous cell carcinoma: knowledge gaps and future direction in assessment and treatment. Internat J Radiat Oncology Biol Physics. 2017;98:868\u201383.","journal-title":"Internat J Radiat Oncology Biol Physics"},{"key":"2567_CR2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.otc.2017.03.013","volume":"50","author":"AV Shetty","year":"2017","unstructured":"Shetty AV, Wong DJ. Systemic treatment for squamous cell carcinoma of the head and neck. Otolaryngol Clin North Am. 2017;50:775\u201382.","journal-title":"Otolaryngol Clin North Am"},{"key":"2567_CR3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.09.009","volume":"62","author":"ME Del Barco","year":"2016","unstructured":"Del Barco ME, Mes\u00eda R, Adansa Klain JC, et al. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03\/VECTITAX study. Oral Oncol. 2016;62:54\u20139.","journal-title":"Oral Oncol"},{"key":"2567_CR4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21053\/ceo.2015.00976","volume":"9","author":"N Denaro","year":"2016","unstructured":"Denaro N, Merlano MC, Russi EG. Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience. Clin Exp Otorhinolaryngol. 2016;9:287\u201397.","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"2567_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12094-017-1776-1","volume":"20","author":"LC Iglesias Docampo","year":"2018","unstructured":"Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2017). Clin Transl Oncol. 2018;20:75\u201383.","journal-title":"Clin Transl Oncol"},{"key":"2567_CR6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"J-P Pignon","year":"2009","unstructured":"Pignon J-P, le Ma\u00eetre A, Maillard E, et al. Meta-analysis of chemotherapy in H cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4\u201314.","journal-title":"Radiother Oncol"},{"key":"2567_CR7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","volume":"23","author":"R Hitt","year":"2012","unstructured":"Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016\u201322.","journal-title":"Ann Oncol"},{"key":"2567_CR8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hed.25923","volume":"41","author":"J Agarwal","year":"2019","unstructured":"Agarwal J, Adulkar D, Swain M, et al. Influence of comorbidity on therapeutic decision making and impact on outcomes in patients with head and neck squamous cell cancers: results from a prospective cohort study. Head Neck. 2019;41:765\u201373.","journal-title":"Head Neck"},{"key":"2567_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2013.11.009","volume":"110","author":"CR B\u00f8je","year":"2014","unstructured":"B\u00f8je CR, Dalton SO, Primdahl H, et al. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol. 2014;110:91\u20137.","journal-title":"Radiother Oncol"},{"key":"2567_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00199","author":"P Szturz","year":"2016","unstructured":"Szturz P, Vermorken JB. Treatment of elderly patients with squamous cell carcinoma of the head and neck. Front Oncol. 2016. https:\/\/doi.org\/10.3389\/fonc.2016.00199 ((Epub ahead of print)).","journal-title":"Front Oncol"},{"key":"2567_CR11","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/cam4.882","volume":"5","author":"I G\u00f6llnitz","year":"2016","unstructured":"G\u00f6llnitz I, Inhestern J, Wendt TG, et al. Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia. Ger Cancer Med. 2016;5:3260\u201371.","journal-title":"Ger Cancer Med"},{"key":"2567_CR12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12254-017-0358-9","volume":"10","author":"T Magnes","year":"2017","unstructured":"Magnes T, Egle A, Greil R, et al. Update on squamous cell carcinoma of the head and neck. Memo. 2017;10:220\u20133.","journal-title":"Memo"},{"key":"2567_CR13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oraloncology.2015.11.019","volume":"53","author":"M-J Ahn","year":"2016","unstructured":"Ahn M-J, D\u2019Cruz A, Vermorken JB, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review. Oral Oncol. 2016;53:10\u20136.","journal-title":"Oral Oncol"},{"issue":"1","key":"2567_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"Pignon JP, le Ma\u00eetre A, Maillard E, Bourhis J; MACH-NC Collaborative Group","year":"2009","unstructured":"Pignon JP, le Ma\u00eetre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta- analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4\u201314. https:\/\/doi.org\/10.1016\/j.radonc.2009.04.014.","journal-title":"Radiother Oncol"},{"key":"2567_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21\u20138.","journal-title":"Lancet Oncol"},{"issue":"10166","key":"2567_CR16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40\u201350 ((Epub 2018 Nov 15. Erratum in: Lancet. 2020\u202f;395(10226):784. P)).","journal-title":"Lancet"},{"key":"2567_CR17","first-page":"JCO2002072","volume":"14","author":"M Gebre-Medhin","year":"2020","unstructured":"Gebre-Medhin M, Brun E, Engstr\u00f6m P, et al. ARTSCAN III: A randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally. Advanced head and neck squamous cell cancer. J Clin Oncol. 2020;14:JCO2002072.","journal-title":"J Clin Oncol"},{"key":"2567_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.09.009","volume":"62","author":"ME Del Barco","year":"2016","unstructured":"Del Barco ME, Mes\u00eda R, Adansa Klain JC, et al. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009\u201303\/VECTITAX study. Oral Oncol. 2016;62:54\u20139.","journal-title":"Oral Oncol"},{"key":"2567_CR19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1634\/theoncologist.2017-0069","volume":"22","author":"M Siano","year":"2017","unstructured":"Siano M, Molinari F, Martin V, et al. Multicenter phase II study of panitumumab in platinum pretreated, advanced head and neck squamous cell cancer. Oncologist. 2017;22:782-e70.","journal-title":"Oncologist"},{"key":"2567_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","volume":"14","author":"JB Vermorken","year":"2013","unstructured":"Vermorken JB, St\u00f6hlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697\u2013710.","journal-title":"Lancet Oncol"},{"key":"2567_CR21","first-page":"75","volume":"9","author":"SB Patel","year":"2015","unstructured":"Patel SB, Gill D, Garrido-Laguna I. Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther. 2015;9:75\u201386.","journal-title":"Onco Targets Ther"},{"key":"2567_CR22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Eng J Med. 2008;359:1116\u201327.","journal-title":"New Eng J Med"},{"issue":"2","key":"2567_CR23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(14)71200-8","volume":"16","author":"J Giralt","year":"2015","unstructured":"Giralt J, Trigo J, Nuyts S, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):221\u201332.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2567_CR24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","volume":"16","author":"R Mes\u00eda","year":"2015","unstructured":"Mes\u00eda R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):208\u201320.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2567_CR25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","volume":"14","author":"JB Vermorken","year":"2013","unstructured":"Vermorken JB, St\u00f6hlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697\u2013710.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2567_CR26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels JP, Ren\u00e9 Leemans C, Golusinski W, Grau C, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462\u201375.","journal-title":"Ann Oncol."},{"issue":"9","key":"2567_CR27","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","volume":"28","author":"MG Ghi","year":"2017","unstructured":"Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer A phase II-III trial. Ann Oncol. 2017;28(9):2206\u201312.","journal-title":"Ann Oncol"},{"issue":"3","key":"2567_CR28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4143\/crt.2015.359","volume":"48","author":"R Kim","year":"2016","unstructured":"Kim R, Hahn S, Shin J, et al. The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis. Cancer Res Treat. 2016;48(3):907\u201316.","journal-title":"Cancer Res Treat"},{"key":"2567_CR29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2020.04.009","volume":"133","author":"G Janoray","year":"2020","unstructured":"Janoray G, Pointreau Y, Alfonsi M, et al. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal\/hypopharyngeal cancer: long-term results of the TREMPLIN randomised GORTEC trial. Eur J Cancer. 2020;133:86\u201393.","journal-title":"Eur J Cancer"},{"key":"2567_CR30","first-page":"8","volume":"45","author":"R Hitt","year":"2020","unstructured":"Hitt R, Iglesias L, L\u00f3pez-Pousa A, et al. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. Clin Transl Oncol. 2020;45:8\u201314.","journal-title":"Clin Transl Oncol"},{"key":"2567_CR31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2019.06.015","volume":"95","author":"M Gau","year":"2019","unstructured":"Gau M, Karabajakian A, Reverdy T, Neidhardt EM, Fayette J. Induction chemotherapy in head and neck cancers: results and controversies. Oral Oncol. 2019;95:164\u20139.","journal-title":"Oral Oncol"},{"key":"2567_CR32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2015-0208","volume":"20","author":"K-W Lee","year":"2015","unstructured":"Lee K-W, Koh Y, Kim S-B, et al. A randomized, multicenter, phase II study of cetuximab with docetaxel and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck cancer. Oncologist. 2015;20:1119\u201320.","journal-title":"Oncologist"},{"key":"2567_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2016.04.030","volume":"96","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Melotek JM, Blair EA, et al. Final results of a randomized phase 2 trial investigating the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation for locoregionally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2016;96:21\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"2567_CR34","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695\u2013704.","journal-title":"N Engl J Med"},{"issue":"9","key":"2567_CR35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","volume":"18","author":"B Lacas","year":"2017","unstructured":"Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221\u201337 ((Erratum in: Lancet Oncol. 2018 Apr;19(4):e184)).","journal-title":"Lancet Oncol."},{"key":"2567_CR36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdy102","volume":"29","author":"RI Haddad","year":"2018","unstructured":"Haddad RI, Posner M, Hitt R, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018;29:1130\u201340.","journal-title":"Ann Oncol"},{"key":"2567_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393:51\u201360.","journal-title":"Lancet"},{"key":"2567_CR38","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","volume":"32","author":"PF Nguyen-Tan","year":"2014","unstructured":"Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014;32:3858\u201366.","journal-title":"J Clin Oncol"},{"issue":"29","key":"2567_CR39","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","volume":"37","author":"BS Chera","year":"2019","unstructured":"Chera BS, Amdur RJ, Green R, et al. Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2019;37(29):2661\u20139.","journal-title":"J Clin Oncol"},{"key":"2567_CR40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2019.08.038","volume":"105","author":"SS Yom","year":"2019","unstructured":"Yom SS, Torres-Saavedra P, Caudell J, et al. NRG-HN002: a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2019;105:684\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2567_CR41","first-page":"2","volume":"6","author":"AJ Rosenberg","year":"2020","unstructured":"Rosenberg AJ, Vokes EE. Optimizing treatment de-escalation in head and neck cancer: current and future perspectives. Oncologist. 2020;6:2.","journal-title":"Oncologist"},{"key":"2567_CR42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2016.4510","volume":"3","author":"LL Siu","year":"2017","unstructured":"Siu LL, Waldron JN, Chen BE, et al. Effect of standard radiotherapy with cisplatin vs. accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol. 2017;3:220\u20136.","journal-title":"JAMA Oncol"},{"key":"2567_CR43","first-page":"22","volume":"19","author":"M Mei","year":"2020","unstructured":"Mei M, Chen YH, Meng T, Qu LH, Zhang ZY, Zhang X. Comparative efficacy and safety of radiotherapy\/cetuximab versusradiotherapy\/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data. Ther Adv Med Oncol. 2020;19:22\u2013132.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"2567_CR44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fonc.2019.00464","volume":"11","author":"P Szturz","year":"2019","unstructured":"Szturz P, Cristina V, Herrera G\u00f3mez RG, Bourhis J, Simon C, Vermorken JB. Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: recommendations for clinical practice. Front Oncol. 2019;11(9):464.","journal-title":"Front Oncol"},{"issue":"3","key":"2567_CR45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CCO.0000000000000526","volume":"31","author":"J Guigay","year":"2019","unstructured":"Guigay J, Le Caer H, Ortholan C, Aup\u00e9rin A, Michel C, Mertens C. Treatment of inoperable elderly head and neck cancer patients. Curr Opin Oncol. 2019;31(3):152\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"2567_CR46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2567_CR47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.21873\/invivo.11816","volume":"34","author":"F De Felice","year":"2020","unstructured":"De Felice F, Pranno N, Papi P, Brugnoletti O, Tombolini V, Polimeni A. Xerostomia and clinical outcomes in definitive intensity modulated radiotherapy (IMRT) Versus three-dimensional conformal radiotherapy (3D-CRT) for head and neck squamous cell carcinoma: a meta-analysis. In Vivo. 2020;34(2):623\u20139.","journal-title":"In Vivo"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02567-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02567-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02567-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T09:47:01Z","timestamp":1624873621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02567-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02567-z","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"7 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Javier Martinez Trufero reports receiving grants for travel and accommodation from Merck, Amgen and Pharmamar. Maria Plana reports receiving grants to provide expert testimony on behalf of Roche, Eisai and Lilly and for travel and accommodation from Merck and MSD. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with th ethical standards of the institutional and\/or national research committtee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}